Roche (RHHBY) announced positive top-line results from a late-study on influenza drug, Xofluza.The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, taken within 48 hours of the symptoms’ onset, to reduce the transmission of influenza within households.Xofluza is approved in several countries for the treatment of uncomplicated influenza types A and B.Year to date, Roche’s shares have risen 9% compared with the industry’s 24.8% growth.Image Source: Zacks Invest ...